Strain-related differences in antibody-mediated changes in gene expression are associated with differences in capsule and location of binding

Fungal Genetics and Biology

Volumn 49, Issue 3, 2012, Pages 227-234

  McClelland, Erin E ^a   Casadevall, Arturo ^b  

^a Geisinger Health Geisinger Commonwealth School of Medicine   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Capsule; Gene expression profile; MAb 18B7; Microarray

Indexed keywords

EPITOPE; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; RNA;

ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL ENCAPSULATION; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENOME ANALYSIS; HUMAN; HUMORAL IMMUNITY; IMMUNOFLUORESCENCE MICROSCOPY; INTERMETHOD COMPARISON; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; SEROTYPE; STRAIN DIFFERENCE;

ANTIBODIES, FUNGAL; ANTIBODIES, MONOCLONAL; CELL WALL; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FUNGAL PROTEINS; GENE EXPRESSION REGULATION, FUNGAL; HUMANS; POLYSACCHARIDES; SPECIES SPECIFICITY;

FILOBASIDIELLA NEOFORMANS;

EID: 84858000144     PISSN: 10871845     EISSN: 10960937     Source Type: Journal    
DOI: 10.1016/j.fgb.2012.01.006     Document Type: Article

References (32)

1. Bryan R.A., Zaragoza O., Zhang T., Ortiz G., Casadevall A., Dadachova E. Radiological studies reveal radial differences in the architecture of the polysaccharide capsule of Cryptococcus neoformans. Eukaryot. Cell 2005, 4:465-475.
2. Casadevall A., Pirofski L. Insights into mechanisms of antibody-mediated immunity from studies with Cryptococcus neoformans. Curr. Mol. Med. 2005, 5:421-433.
3. Casadevall A., Cleare W., Feldmesser M., Glatman-Freedman A., Goldman D.L., Kozel T.R., Lendvai N., Mukherjee J., Pirofski L.A., Rivera J., et al. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob. Agents Chemother. 1998, 42:1437-1446.
4. Dadachova E., Bryan R.A., Huang X., Ortiz G., Moadel T., Casadevall A. Comparative evaluation of capsular polysaccharide-specific IgM and IgG antibodies and F(ab')2 and Fab fragments as delivery vehicles for radioimmunotherapy of fungal infection. Clin. Cancer Res. 2007, 13:5629s-5635s.
5. Datta K., Pirofski L.A. Towards a vaccine for Cryptococcus neoformans: principles and caveats. FEMS Yeast Res. 2006, 6:525-536.
6. Edgar R., Domrachev M., Lash A.E. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucl. Acids Res. 2002, 30:207-210.
7. Fan W., Kraus P.R., Boily M.J., Heitman J. Cryptococcus neoformans gene expression during murine macrophage infection. Eukaryot. Cell 2005, 4:1420-1433.
8. Idnurm A., Heitman J. Ferrochelatase is a conserved downstream target of the blue light-sensing white collar complex in fungi. Microbiology 2010, 156:2393-2407.
9. Janda A., Casadevall A. Circular dichroism reveals evidence of coupling between immunoglobulin constant and variable region secondary structure. Mol. Immunol. 2010, 47:1421-1425.
10. 2 sensing pathway via differential expression of carbonic anhydrase in Cryptococcus neoformans. Genetics 2010, 185:1207-1219.
11. Kraus P.R., Boily M.J., Giles S.S., Stajich J.E., Allen A., Cox G.M., Dietrich F.S., Perfect J.R., Heitman J. Identification of Cryptococcus neoformans temperature-regulated genes with a genomic-DNA microarray. Eukaryot. Cell 2004, 3:1249-1260.
12. Kwon-Chung K.J., Varma A. Do major species concepts support one, two or more species within Cryptococcus neoformans?. FEMS Yeast Res. 2006, 6:574-587.
13. Larsen R.A., Pappas P.G., Perfect J., Aberg J.A., Casadevall A., Cloud G.A., James R., Filler S., Dismukes W.E. Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob. Agents Chemother. 2005, 49:952-958.
14. Macura N., Zhang T., Casadevall A. Dependence of macrophage phagocytic efficacy on antibody concentration. Infect Immun. 2007, 75:1904-1915.
15. Maeng S., Ko Y.J., Kim G.B., Jung K.W., Floyd A., Heitman J., Bahn Y.S. Comparative transcriptome analysis reveals novel roles of the Ras and cyclic AMP signaling pathways in environmental stress response and antifungal drug sensitivity in Cryptococcus neoformans. Eukaryot. Cell 2010, 9:360-378.
16. Magliani W., Conti S., Arseni S., Salati A., Ravanetti L., Maffei D.L., Giovati L., Polonelli L. Antibody-mediated protective immunity in fungal infections. New Microbiol. 2005, 28:299-309.
17. McClelland E.E., Nicola A.M., Prados-Rosales R., Casadevall A. Ab binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism. J. Clin. Invest. 2010, 120:1355-1361.
18. Mukherjee J., Scharff M.D., Casadevall A. Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Immun. 1992, 60:4534-4541.
19. Mukherjee J., Casadevall A., Scharff M.D. Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization. J. Exp. Med. 1993, 177:1105-1116.
20. Mukherjee J., Pirofski L.A., Scharff M.D., Casadevall A. Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Proc. Natl. Acad. Sci. USA 1993, 90:3636-3640.
21. Mukherjee J., Zuckier L.S., Scharff M.D., Casadevall A. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Antimicrob. Agents Chemother. 1994, 38:580-587.
22. Mukherjee S., Lee S., Mukherjee J., Scharff M.D., Casadevall A. Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice. Infect Immun. 1994, 62:1079-1088.
23. Mukherjee J., Scharff M.D., Casadevall A. Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains. Infect Immun. 1995, 63:3353-3359.
24. Nussbaum G., Cleare W., Casadevall A., Scharff M.D., Valadon P. Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy. J. Exp. Med. 1997, 185:685-694.
25. Peachey P.R., Gubbins P.O., Martin R.E. The association between cryptococcal variety and immunocompetent and immunocompromised hosts. Pharmacotherapy 1998, 18:255-264.
26. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucl. Acids Res. 2001, 29:e45.
27. Philip B., Levin D.E. Wsc1 and Mid2 are cell surface sensors for cell wall integrity signaling that act through Rom2, a guanine nucleotide exchange factor for Rho1. Mol. Cell. Biol. 2001, 21:271-280.
28. Subramaniam K., Metzger B., Hanau L.H., Guh A., Rucker L., Badri S., Pirofski L.A. IgM(+) memory B cell expression predicts HIV-associated cryptococcosis status. J. Infect. Dis. 2009, 200:244-251.
29. Yano, M., Gohil, S., Coleman, J.R., Manix, C., Pirofski, L.A., 2011. Antibodies to Streptococcus pneumoniae capsular polysaccharide enhance pneumococcal quorum sensing. mBio 2, e00176-e00111.
30. Zaragoza O., Casadevall A. Monoclonal antibodies can affect complement deposition on the capsule of the pathogenic fungus Cryptococcus neoformans by both classical pathway activation and steric hindrance. Cell. Microbiol. 2006, 8:1862-1876.
31. Zaragoza O., Rodrigues M.L., De Jesus M., Frases S., Dadachova E., Casadevall A. The capsule of the fungal pathogen Cryptococcus neoformans. Adv. Appl. Microbiol. 2009, 68:133-216.
32. Zebedee S.L., Koduri R.K., Mukherjee J., Mukherjee S., Lee S., Sauer D.F., Scharff M.D., Casadevall A. Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans. Antimicrob. Agents Chemother. 1994, 38:1507-1514.